Current and Future Perspectives of LDL-C Lowering Therapies 2026 - PubMed
2 hours ago
- #cardiovascular prevention
- #LDL-C lowering therapies
- #emerging treatments
- LDL-cholesterol (LDL-C) is a key cause of atherosclerotic cardiovascular disease (ASCVD), and lowering it is vital for prevention.
- Since statins were introduced, therapies have expanded to include ezetimibe, PCSK9-targeting agents, bempedoic acid, and other emerging options.
- This review covers patient evaluation, treatment targets for primary and secondary prevention, statin use, and managing statin intolerance, including the nocebo effect.
- Non-statin therapies like ezetimibe, PCSK9 inhibitors, inclisiran, and bempedoic acid are discussed for their mechanisms, efficacy, and clinical positioning.
- Advanced treatments for severe dyslipidemia, such as lipoprotein apheresis, lomitapide, and evinacumab, are reviewed.
- Future directions include oral PCSK9 inhibitors, next-generation CETP inhibitors, lipoprotein(a)-lowering agents, and genome-editing approaches to meet unmet needs, especially in familial hypercholesterolemia, statin intolerance, and residual risk.